Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

Subsai Kongsaengdao; Narong Maneeton; Benchalak Maneeton

doi:10.2147/NDT.S152252

Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

Neuropsychiatr Dis Treat. 2018 Apr 26:14:1119-1124. doi: 10.2147/NDT.S152252. eCollection 2018.

Authors

Subsai Kongsaengdao^{1

2}, Narong Maneeton³, Benchalak Maneeton³

Affiliations

¹ Division of Neurology, Department of Medicine, Rajavithi Hospital, Department of Medical Services, Public Health Ministry, Bangkok, Thailand.
² Department of Medicine, College of Medicine, Rangsit University, Bangkok, Thailand.
³ Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Abstract

Background: The short-term quality of life (QoL) in cervical dystonia (CD) after treating with abobotulinum toxin A (Abo-BTX A) and neubotulinum toxin A (Neu-BTX A) have been studied in Thai CD patients. However; the long-term study has not been published.

Objective: The aim of the present study was to determine long-term improvement of the health-related quality of life (HRQoL) after eight injections of Abo-BTX A over 2 years in CD patients.

Patients and methods: A 2-year prospective study on the QoL of CD patients, as measured by HRQoL, before and after receiving eight injections of Abo-BTX A at 3-month intervals over a 2-year treatment period was performed. The disease-specific HRQoL was assessed before and after the treatment by using the Cervical Dystonia Impact Profile-58 (CDIP-58) questionnaire. The general HRQoL was assessed by using the Medical Outcomes 36-Item Short Form Health Survey (SF-36), while depressive disorder screening was assessed by using the Center of Epidemiologic Studies-Depression (CES-D) questionnaire. The SF-36 and CES-D questionnaire were administered before treatment and every 3 months before the next injection for a 2-year period.

Results: A total of 20 CD patients were enrolled from January 2013 to December 2015. CDIP-58 showed a significant improvement after long-term injections of Abo-BTX A in all domains (P < 0.001). However, only vitality domain of SF-36, which assessed general HRQoL, showed a significant improvement after long-term injections (P = 0.037). There was no prevalence of depressive disorder in all patients (CES-D score <20) in this study.

Conclusion: The Abo-BTX A injections at 3-month intervals over a 2-year period improved the CDIP-58 scores, which assess disease-specific HRQoL, as well as an increased vitality domain of general HRQoL. No patient suffered from depression in this study.

Keywords: 36-Item Short Form Health Survey; Cervical Dystonia Impact Profile-58 questionnaire; abobotulinum toxin A; cervical dystonia; depressive disorder; health-related quality of life.